Ovid Therapeutics Inc. — Form 10-Q
Filed August 13, 2026 · analyzed by the Periodic Agent
10-Q
— Neutral
significance 22/100
What the filing says
Ovid Therapeutics entered a one-year consulting agreement with Karen Bernstein, effective June 10, 2026, for $45,000 in cash fees ($3,750/month) plus a grant of 50,000 non-statutory stock options vesting June 9, 2027 at fair-market-value exercise price. Bernstein provides strategic advice to the CEO; the agreement includes standard confidentiality, IP assignment, and independent contractor terms.
Why this rating
Routine consulting hire; $45K cash is 0.2% of $22.2M market cap, 50K options immaterial at current scale. Standard governance.
See more from August 13, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.